Article

Integrative Proteogenomic and Single-Cell Analysis Reveals RTK Switching and Metabolic Reprogramming as Synthetic Lethal Vulnerabilities in FGFR Inhibitor Resistance

2026-02-26

Abstract excerpt

<title>Abstract</title> <p> Background Although fibroblast growth factor receptor (FGFR) inhibitors (FGFRi) have demonstrated clinical promise, the inevitable emergence of acquired resistance remains a distinct bottleneck, severely compromising their long-term clinical efficacy. The pan-cancer molecular landscape and heterogeneous mechanisms driving this resistance, ranging from genetic alterations to dynamic n...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cfdc7b3d-aa42-542e-8637-6395c2357e49
DOI: 10.21203/rs.3.rs-8869688/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Integrative Proteogenomic and Single-Cell Analysis Reveals RTK Switching and Metabolic Reprogramming as Synthetic Lethal Vulnerabilities in FGFR Inhibitor ResistanceDOI 10.21203/rs.3.rs-8869688/v1Read

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.Semantic proximity Read

Integrated Genomic Profiling Reveals Mechanisms of Broad Drug Resistance and Opportunities for Phenotypic Reprogramming in Cancer CellsSemantic proximity Read

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.Semantic proximity Read

IGF2 associated PI3K signaling shapes temozolomide sensitivity in glioblastomaSemantic proximity Read

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.Semantic proximity Read

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Semantic proximity Read

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.Semantic proximity Read

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancerSemantic proximity Read

Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomasSemantic proximity Read

Single-cell lineage analysis reveals genetic and epigenetic interplay in glioblastoma drug resistanceSemantic proximity Read

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read